Financial Result for the financial year ending March 31, 2025 Board meeting held on May 30, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 12.6 pts less than Nifty Microcap 250 and 12.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Coral Laboratories reported audited standalone results for FY25 with revenue from operations rising 37.5% YoY to ₹11,500.53 lakhs (vs ₹8,366.04 lakhs in FY24). Total income grew to ₹12,411.39 lakhs. Profit before exceptional items and tax jumped 59% to ₹3,323.98 lakhs, while profit after tax grew 53% to ₹2,415.56 lakhs (vs ₹1,578.90 lakhs). EPS rose to ₹67.61 from ₹44.19. The board recommended a 15% final dividend (₹1.50 per share on ₹10 face value). Q4 PAT of ₹282.71 lakhs was significantly lower than Q3 FY25 (₹614.45 lakhs) due to a ₹76.96 lakh exceptional item for earlier-year tax provision. The statutory auditor issued an unmodified opinion. Reserves stood at ₹19,763.32 lakhs, and operating cash flow turned positive at ₹733.15 lakhs (vs ₹488.47 lakhs).
Strong full-year performance with healthy revenue and profit growth, supported by a positive dividend and clean audit opinion, is positive for shareholders. However, the sharp sequential drop in Q4 PAT due to the one-time tax provision may draw short-term attention from investors.